At PrEP Biopharm, we are developing a new approach to leverage the innate immune system to address this unmet medical need. Prep Biopharm Limited is an independent, development stage biopharmaceutical company focused on the prevention of respiratory infections. The privately held company’s flagship product, PrEP-001, is in phase 2 for the prevention of upper respiratory tract viral infections which is expected to be a countermeasure against respiratory viral pandemics, including COVID 19. Protective effect has been demonstrated against influenza A and rhinovirus 16 in phase 2a studies and against SARS, MERS, RSV in mouse studies. Also expected use in non-pandemic settings in asthma & COPD patients to prevent exacerbations triggered by respiratory viruses.